We caught up with Dr Satu Vainikka, CEO of VAL at this year UK Investors Show held in the QE2 building in London.
WideCells Group PLC (LON:WDC) New Media Business Created
New Media Business Created, Board Appointments and Proposed Name Change to Iconic Labs Plc
NetScientific PLC (LON:NSCI) Share Price Movement
NetScientific plc (AIM: NSCI) notes its recent share price movement and confirms that it is not aware of any reason for such movement.
Faron Pharmaceuticals Ltd (LON:FARN) UK CTA approval
Substantial immune activation taking place post-Clevegen administration UK CTA approval
Motif Bio PLC (LON:MTFB) Complete Response Letter from the FDA
Graham Lumsden, Chief Executive Officer of Motif Bio, said: “We are disappointed for patients and providers seeking an alternative antibiotic to treat ABSSSI. We intend to request a meeting with
OKYO Pharma Limited (LON:OKYO) Corporate Update
Since its inception the company (OKYO Pharma Ltd. ”OKYO”) has progressed its R&D programs focused on its assets Chemerin and BAM8.
Angle PLC (AIM:AGL/OTCQX:ANPCY) BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
Research using Parsortix to isolate CTC clusters from blood identifies drugs which dissociate highly metastatic CTC clusters resulting in a near total elimination of metastasis in animal models
SALVARX GROUP PLC (LON:SALV) Result of AGM and Completion of Disposal and Demerger
SalvaRx (AIM: SALV), the drug discovery and development company focused on cancer immunotherapy, is pleased to announce that at its Annual General Meeting held earlier today all resolutions set out
Immupharma PLC (LON:IMM) Update on Corporate Activities
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to provide an update on ongoing activities.
Faron Pharma. Oy (LON:FARN) Patient subgroup identified from INTEREST trial
Dr Markku Jalkanen, CEO of Faron, said: “We have, and are continuing to build, a solid body of evidence which indicates that there is clearly a subgroup of patients for
N4 Pharma PLC (AIM:N4P) Research collaboration update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, today provides an update on its collaboration with MedImmune, following the
